Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-6 vs Lonapegsomatropin (Skytrofa)
An educational, source-based comparison of GHRP-6 and Lonapegsomatropin (Skytrofa) — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide ghrelin receptor (GHS-R1a) agonist that stimulates pituitary GH release and increases appetite via central ghrelin pathways. One of the earliest GH-releasing peptides studied.
- Endogenous GH pulse stimulation
- Appetite stimulation in cachexia models
- Cardioprotective signaling (preclinical)
- • Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- • Not FDA-approved; banned by WADA.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHRP-6 | GHRP-6 and the ghrelin receptor: cardiometabolic effects | Cardiovascular Research | 2010 | Review of GH-independent cardioprotective signaling observed in animal models. |
| Lonapegsomatropin (Skytrofa) | heiGHt trial | JCEM | 2021 | Non-inferior annualized height velocity vs daily somatropin. |
Side-effect & safety grid
- Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- Not FDA-approved; banned by WADA.
- FDA-approved.
- Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHRP-6 vs Lonapegsomatropin (Skytrofa) — Key differences
- Class: GHRP-6 is classified as Growth Hormone Axis, while Lonapegsomatropin (Skytrofa) is GH Analog · Endocrine.
- Primary research focus: GHRP-6 — endogenous gh pulse stimulation; Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency.
- Tag: Growth hormone · Appetite vs FDA-Approved · Endocrine.